Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques

Metabolism: Clinical and Experimental

Volumn 45, Issue 4, 1996, Pages 463-468

  Obasanjo, Iyabo O ^a   Clarkson, Thomas B ^b   Weaver, David S ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NANDROLONE DECANOATE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HORMONE ACTION; MACACA; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL;

EID: 0029983303     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90220-6     Document Type: Article

References (48)

1. Council on Scientific Affairs: Medical and nonmedical uses of anabolic-androgenic steroids. JAMA 264:2923-2927, 1990
2. Huie M: An acute myocardial infarction occurring in an anabolic steroid user. Med Sci Sports Exerc 26:408-413, 1994
3. Luke JL, Farb A, Virmani R, et al: Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: Pathological and toxicological findings. J Forensic Sci 35:1441-1447, 1990
4. Ferenchick GS, Adelman S: Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter. Am Heart J 124:507-508, 1992
5. McNutt RA, Ferenchick GS, Kirlin PC, et al: Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol 62:164, 1988 (letter)
6. Mochizuki RM, Richter KJ: Cardiomyopathy and cerebrovascular accident associated with anabolic steroid use. Physician Sports Med 16:109-114, 1988
7. Laroche GP: Steroid anabolic drugs and arterial complications in an athlete - A case history. Angiology 41:964-969, 1990
8. Dequeker J, Guesens P: The past, the present and the future of the anabolic steroid nandrolone decanoate treatment for osteoporosis, in Christiansen C, Overgaard K (eds): Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis. Copenhagen, Denmark, Osteopress, 1990, pp 2007-2011
9. Aerssens J, Van Audekercke R, Guesens P, et al: Mechanical properties, bone mineral content, and bone composition (collagen osteocalcin, IGF-I) of the rat femur: Influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment. Calcif Tissue Int 53:269-277, 1993
10. Passeri M, Pedrazzonu M, Pioli G, et al: Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas 17:211-219, 1993
11. Gennari C, AgnusDei D, Gonneli S, et al: Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: A double blind study. Maturitas 11:187-197, 1989
12. Need AG, Chatterton BE, Walker CJ, et al: Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. Maturitas 8:275-280, 1986
13. Need AG, Nordin BE, Chatterton BE: Double-blind placebo-controlled trial of treatment of osteoporosis with anabolic nandrolone decanoate. Osteoporosis Int 3:S218-S222, 1993 (suppl 1)
14. Adams MR, Kaplan JR, Manuck SB, et al: Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of effect of added progesterone. Arteriosclerosis 10:1051-1057, 1990
15. Allain CC, Poon LS, Chan CSG, et al: Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475, 1974
16. Fossati P, Principe L: Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 28:2077-2080, 1982
17. Lipid Research Clinics Program: Manual of Laboratory Operations, vol 1: Lipid and Lipoprotein Analysis. Bethesda, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, DHEW publication no. (NIH) 75-268, 1974
18. Wilson ME, Gordon TP, Rudman CG, et al: Effects of a natural versus artificial environment on the tempo of maturation in female rhesus monkeys. Endocrinology 123:2653-2661, 1988
19. Clarkson TB, Prichard RW, Morgan TM, et al: Remodeling of coronary arteries in human and non-human primates. JAMA 271:289-294, 1994
20. SAS Institute: SAS User's Guide: Statistics, version 5. Cary, NC, SAS Institute, 1985
21. Kuipers H, Wijnen JAG, Hartgens F, et al: Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med 12:413-418, 1991
22. Hassager C, Podenphat J, Riis BJ, et al: Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism 8:238-242, 1989
23. Birkenhager JC, Erdtsieck RJ, Zeelenberg J, et al: Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis? Bone Miner 18:251-265, 1992
24. Glazer G, Suchman AL: Lack of demonstrated effect of nandrolone on serum lipids. Metabolism 43:204-210, 1994
25. Fahraeus L, Larsson-Cohn U, Wallentin L: Lipoproteine during oral and cutaneous administration of oestradiol-17beta to menopausal women. Acta Androl 101:597-602, 1982
26. Adami S, Rossini M, Zamberlan N, et al: Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 17:191-196, 1993
27. Glazer G: Atherogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med 151:1925-1933, 1991
28. Clarkson TB, Adams MR, Wagner JD, et al: Experimental effects of estradiol deprivation and replacement on atherosclerosis, in Christiansen C, Overgaard K (eds): Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis. Copenhagen, Denmark, Osteopress, 1990, pp 1928-1935
29. Johnson M, Ramey E, Ramwell PW: Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 232:H381-H385, 1977
30. Pilo R, Aharony D, Raz A: Testosterone potentiation of ionophore and ADP induced platelet aggregation: Relationship to arachidonic acid metabolism. Thromb Haemost 46:538-542, 1981
31. Rosenbaum WI, El-Sabban F, Nelson GH, et al: Effects in mice of testosterone and dihydrotestosterone on platelet aggregation in injured arterioles and ex-vivo. Thromb Res 45:719-728, 1987
32. Cembrano J, Lillo M, Val J, et al: Influence of sex difference and hormones on elastin and collagen in the aorta of chickens. Circ Res 8:527-529, 1960
33. Greenberg S, George WR, Kadowitz PJ, et al: Androgen-induced enhancement of vascular reactivity. Can J Physiol Pharmacol 52:14-22, 1973
34. Lin AL, McGill HC, Shain SA: Hormone receptors of the baboon cardiovascular system. Circ Res 50:610-616, 1982
35. McGill HC, Anselmo VC, Buchanan JM, et al: The heart is a target organ for androgen. Science 207:775-777, 1980
36. Ferrer M, Encabo A, Marin J, et al: Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur J Pharmacol 252:233-241, 1994
37. Friedl KE, Hannan CJ, Jones RE, et al: High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 39:69-74, 1990
38. Adams MR, Williams JK, Kaplan JR: Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 15:562-570, 1995
39. The Coronary Drug Project Research Group: The Coronary Drug Project: Initial findings leading to modifications of its research protocol. JAMA 214:1303-1313, 1970
40. The Coronary Drug Project Research Group: The Coronary Drug Project. Findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA 226:652-657, 1973
41. Raeside JI, Renaud RL, Friendship RM: Aromatization of 19-norandrogens by porcine Leydig cells. J Steroid Biochem 32:729-735, 1989
42. Dintinger T, Gaillard J, Zwain I, et al: Synthesis and aromatization of 19-norandrogens in the stallion testis. J Steroid Biochem 32:537-544, 1989
43. Longcope C, Pratt JH, Schneider SH, et al: Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab 46:146-152, 1978
44. Anderson F: Kinetics and pharmacology of estrogens in preand postmenopausal women. Int J Fertil 38:53-64, 1993 (suppl 1)
45. Meldrum DR, Davidson BJ, Tataryn IV, et al: Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 57:624-628, 1981
46. Longcope C, Baker R, Johnston CC: Androgen and estrogen metabolism: Relationship to obesity. Metabolism 35:235-237, 1986
47. Davis WM, Long SF, Lin T: Nandrolone decanoate reduces the premature mortality of cardiomyopathic hamsters. Res Commun Chem Pathol Pharmacol 81:21-32, 1993
48. Braden GA, Herrington DM, Downes TR, et al: Qualitative and quantitative contrasts in the mechanisms of lumen enlargement by coronary balloon angioplasty and directional coronary atherectomy. J Am Coll Cardiol 23:40-48, 1994